Dihydronovobiocin is a semi-synthetic member of the novobiocin aminocoumarin antibiotic family prepared by reduction of the prenyl double bond and published in 1956. Dihydronovobiocin is an inhibitor of the bacterial type II topoisomerase, DNA gyrase. Dihydronovobiocin is equipotent to novobiocin against S. aureus in vivo, including resistant strains, and is active against Mycobacterium tuberculosis. Dihydronovobiocin entered clinical development in the 1960s but did not progress to market.
| Molecular Formula | C31H38N2O11 |
| References | Rolland G et la (1956) Novobiocin and some derivatives. Farmaco, Edizione Scientifica 11:549 Solotorovsky M et al (1958) Microbiological activity of novobiocin. Antibiot. Chemother. 8:86 Tacquet A et al (1959) The in vitro and in vivo antituberculous activity of dihydronovobiocin. Ann. de l'Institut Pasteur de Lille 10:61 |